PDCD5 regulates cell proliferation, cell cycle progression and apoptosis

Li,Penghui; Fei,Hongxin; Wang,Lihong; Xu,Huiyu; Zhang,Haiyan; Zheng,Lihong

doi:10.3892/ol.2017.7401

PDCD5 regulates cell proliferation, cell cycle progression and apoptosis

Authors:
- Penghui Li
- Hongxin Fei
- Lihong Wang
- Huiyu Xu
- Haiyan Zhang
- Lihong Zheng
View Affiliations

Affiliations: Department of Biogenetics, Qiqihar Medical University, Qiqihar, Heilongjiang 161006, P.R. China, Department of Histology and Embryology, Qiqihar Medical University, Qiqihar, Heilongjiang 161006, P.R. China, Department of Immunology, Qiqihar Medical University, Qiqihar, Heilongjiang 161006, P.R. China
Published online on: November 14, 2017 https://doi.org/10.3892/ol.2017.7401
Pages: 1177-1183

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Programmed cell death (PDCD)5 is cloned from human leukemia cell line TF‑1. PDCD5 is one of the members of the programmed cell death protein family that is frequently involved in tumor growth and apoptosis. To investigate the molecular and cellular functions of PDCD5, the present study established a PDCD5 stably overexpressing A431 cell line and examined the role of PDCD5 in cell proliferation, cell cycle progression and apoptosis. The data demonstrated that overexpression of PDCD5 significantly inhibited cell proliferation, induced cell cycle arrest at G2/M phase and apoptosis in A431 cells. The expression profiles of certain key regulators of these cellular events were further investigated, including P53, B cell lymphoma (BCL)‑2, BCL‑2 associated X protein (BAX) and caspase (CASP)3. The data demonstrated that at the transcript and protein levels, P53, BAX and CASP3 were all upregulated in the PDCD5 stably overexpressing A431 cells whereas BCL‑2 was downregulated, indicating that PDCD5 acts as an important upstream regulator of P53, BCL‑2, BAX and CASP3. The data suggest that PDCD5 regulates cell proliferation, cell cycle progression and apoptosis in A431 cells. PDCD5 may be a novel tumor suppressor gene, and may be potentially used for cancer treatment in the future.

View Figures

View References

1	Hipfner DR and Cohen SM: Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol. 5:805–815. 2004. View Article : Google Scholar : PubMed/NCBI
2	Löbrich M and Jeggo PA: The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer. 7:861–869. 2007. View Article : Google Scholar : PubMed/NCBI
3	Alenzi FQ: Links between apoptosis, proliferation and the cell cycle. Br J Biomed Sci. 61:99–102. 2004. View Article : Google Scholar
4	Liu H, Wang Y, Zhang Y, Song Q, Di C, Chen G, Tang J and Ma D: TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun. 254:203–210. 1999. View Article : Google Scholar : PubMed/NCBI
5	Wang N, Lu HS, Guan ZP, Sun TZ, Chen YY, Ruan GR, Chen ZK, Jiang J and Bai CJ: Involvement of PDCD5 in the regulation of apoptosis in fibroblast-like synoviocytes of rheumatoid arthritis. Apoptosis. 12:1433–1441. 2007. View Article : Google Scholar : PubMed/NCBI
6	Chen LN, Wang Y, Ma DL and Chen YY: Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression. Apoptosis. 11:101–111. 2006. View Article : Google Scholar : PubMed/NCBI
7	Yang YH, Zhao M, Li WM and Lu YY, Chen YY, Kang B and Lu YY: Expression of programmed cell death 5 gene involves in regulation of apoptosis in gastric tumor cells. Apoptosis. 11:993–1001. 2006. View Article : Google Scholar : PubMed/NCBI
8	Ruan GR, Zhao HS, Chang Y, Li JL, Qin YZ, Liu YR, Chen SS and Huang XJ: Adenovirus-mediated PDCD5 gene transfer sensitizes K562 cells to apoptosis induced by idarubicin in vitro and in vivo. Apoptosis. 13:641–648. 2008. View Article : Google Scholar : PubMed/NCBI
9	Salvi M, Xu D, Chen Y, Cabrelle A, Sarno S and Pinna LA: Programmed cell death protein 5 (PDCD5) is phosphorylated by CK2 in vitro and in 293T cells. Biochem Biophys Res Commun. 387:606–610. 2009. View Article : Google Scholar : PubMed/NCBI
10	Li G, Ma D and Chen Y: Cellular functions of programmed cell death 5. Biochim Biophys Acta. 1863:572–580. 2016. View Article : Google Scholar : PubMed/NCBI
11	Wang Y, Li X, Wang L, Ding P, Zhang Y, Han W and Ma D: An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J Cell Sci. 117:1525–1532. 2004. View Article : Google Scholar : PubMed/NCBI
12	Zhang S, Li G, Fu X, Qi Y, Li M, Lu G, Hu J, Wang N, Chen Y, Bai Y and Cui M: PDCD5 protects against cardiac remodeling by regulating autophagy and apoptosis. Biochem Biophys Res Commun. 461:321–328. 2015. View Article : Google Scholar : PubMed/NCBI
13	Li H, Wang Q, Gao F, Zhu F, Wang X, Zhou C, Liu C, Chen Y, Ma C, Sun W and Zhang L: Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas. Oncol Rep. 20:573–579. 2008.PubMed/NCBI
14	Du YJ, Xiong L, Lou Y, Tan WL and Zheng SB: Reduced expression of programmed cell death 5 protein in tissue of human prostate cancer. Chin Med Sci J. 24:241–245. 2009. View Article : Google Scholar : PubMed/NCBI
15	Chen C, Zhou H, Xu L, Liu X, Liu Z, Ma D, Chen Y and Ma Q: Prognostic significance of downregulated expression of programmed cell death 5 in chondrosarcoma. J Surg Oncol. 102:838–843. 2010. View Article : Google Scholar : PubMed/NCBI
16	Zhang X, Wang X, Song X, Wei Z, Zhou C, Zhu F, Wang Q, Ma C and Zhang L: Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas. Oncol Rep. 25:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Wang GH and Zhang QY: Determination of PDCD5 in peripheral blood serum of cancer patients. Chin J Cancer Res. 23:224–228. 2011. View Article : Google Scholar : PubMed/NCBI
18	Gao M, Gao W, Wang Z, Liu Y, Li Y, Wei C, Sun Y, Guo C, Zhang L, Wei Z and Wang X: The reduced PDCD5 protein is correlated with the degree of tumor differentiation in endometrioid endometrial carcinoma. Springerplus. 5:9882016. View Article : Google Scholar : PubMed/NCBI
19	Chen Y, Zou Z, Xu A, Liu Y, Pan H and Jin L: Serum programmed cell death protein 5 (PDCD5) levels is upregulated in liver diseases. J Immunoassay Immunochem. 34:294–304. 2013. View Article : Google Scholar : PubMed/NCBI
20	Xu F, Wu K, Zhao M, Qin Y and Xia M: Expression and clinical significance of the programmed cell death 5 gene and protein in laryngeal squamous cell carcinoma. J Int Med Res. 41:1838–1847. 2013. View Article : Google Scholar : PubMed/NCBI
21	Wang D, Wang W, Song CL and Xia P: The roles of serum PDCD5 in circulating CD133 positive cells of the patients with gastric cancer. Tumour Biol. 37:11799–11804. 2016. View Article : Google Scholar : PubMed/NCBI
22	Wang W, Song XW and Zhao CH: Roles of programmed cell death protein 5 in inflammation and cancer (Review). Int J Oncol. 49:1801–1806. 2016. View Article : Google Scholar : PubMed/NCBI
23	Shi L, Song Q, Zhang Y, Lou Y and Wang Y, Tian L, Zheng Y, Ma D, Ke X and Wang Y: Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells. Biochem Biophys Res Commun. 396:224–230. 2010. View Article : Google Scholar : PubMed/NCBI
24	Yin A, Jiang Y, Zhang X, Zhao J and Luo H: Transfection of PDCD5 sensitizes colorectal cancer cells to cisplatin-induced apoptosis in vitro and in vivo. Eur J Pharmacol. 649:120–126. 2010. View Article : Google Scholar : PubMed/NCBI
25	Xu HY, Chen ZW, Pan YM, Fan L, Guan J and Lu YY: Transfection of PDCD5 effect on the biological behavior of tumor cells and sensitized gastric cancer cells to cisplatin-induced apoptosis. Dig Dis Sci. 57:1847–1856. 2012. View Article : Google Scholar : PubMed/NCBI
26	Han XR, Sun Y and Bai XZ: The anti-tumor role and mechanism of integrated and truncated PDCD5 proteins in osteosarcoma cells. Cell Signal. 24:1713–1721. 2012. View Article : Google Scholar : PubMed/NCBI
27	Li Y, Zhou G, La L, Chi X, Cao Y, Liu J, Zhang Z, Chen Y and Wu B: Transgenic human programmed cell death 5 expression in mice suppresses skin cancer development by enhancing apoptosis. Life Sci. 92:1208–1214. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zhu W, Li Y and Gao L: Cisplatin in combination with programmed cell death protein 5 increases antitumor activity in prostate cancer cells by promoting apoptosis. Mol Med Rep. 11:4561–4566. 2015. View Article : Google Scholar : PubMed/NCBI
29	Fu DZ, Cheng Y, He H, Liu HY and Liu YF: Recombinant human PDCD5 exhibits an antitumor role in hepatocellular carcinoma cells via clathrin-dependent endocytosis. Mol Med Rep. 12:8135–8140. 2015. View Article : Google Scholar : PubMed/NCBI
30	Gao L, Ye X, Ma RQ, Cheng HY, Han HJ, Cui H, Wei LH and Chang XH: Low programmed cell death 5 expression is a prognostic factor in ovarian cancer. Chin Med J (Engl). 128:1084–1090. 2015. View Article : Google Scholar : PubMed/NCBI
31	Xiao J, Li G, Hu J, Qu L, Ma D and Chen Y: Anti-inflammatory effects of recombinant human PDCD5 (rhPDCD5) in a rat collagen-induced model of arthritis. Inflammation. 38:70–78. 2015. View Article : Google Scholar : PubMed/NCBI
32	Xiao J, Liu W, Chen Y and Deng W: Recombinant human PDCD5 (rhPDCD5) protein is protective in a mouse model of multiple sclerosis. J Neuroinflammation. 12:1172015. View Article : Google Scholar : PubMed/NCBI
33	Lu J, Jiang Z, Chen Y, Zhou C and Chen C: Knockout of programmed cell death 5 (PDCD5) gene attenuates neuron injury after middle cerebral artery occlusion in mice. Brain Res. 1650:152–161. 2016. View Article : Google Scholar : PubMed/NCBI
34	Spinola M, Meyer P, Kammerer S, Falvella FS, Boettger MB, Hoyal CR, Pignatiello C, Fischer R, Roth RB, Pastorino U, et al: Association of the PDCD5 locus with lung cancer risk and prognosis in smokers. J Clin Oncol. 24:1672–1678. 2006. View Article : Google Scholar : PubMed/NCBI
35	Nanba K, Toyooka S, Soh J, Tsukuda K, Yamamoto H, Sakai A, Ouchida M, Kobayashi N, Matsuo K, Koide N, et al: The allelic distribution of a single nucleotide polymorphism in the PDCD5 gene locus of Japanese non-small cell lung cancer patients. Mol Med Rep. 1:667–671. 2008.PubMed/NCBI
36	Xu L, Chen Y, Song Q, Xu D, Wang Y and Ma D: PDCD5 interacts with Tip60 and functions as a cooperator in acetyltransferase activity and DNA damage-induced apoptosis. Neoplasia. 11:345–354. 2009. View Article : Google Scholar : PubMed/NCBI
37	Yao H, Feng Y, Zhou T, Wang J and Wang ZX: NMR studies of the interaction between human programmed cell death 5 and human p53. Biochemistry. 51:2684–2693. 2012. View Article : Google Scholar : PubMed/NCBI
38	Xu L, Hu J, Zhao Y, Hu J, Xiao J, Wang Y, Ma D and Chen Y: PDCD5 interacts with p53 and functions as a positive regulator in the p53 pathway. Apoptosis. 17:1235–1245. 2012. View Article : Google Scholar : PubMed/NCBI
39	Tracy CM, Gray AJ, Cuéllar J, Shaw TS, Howlett AC, Taylor RM, Prince JT, Ahn NG, Valpuesta JM and Willardson BM: Programmed cell death protein 5 interacts with the cytosolic chaperonin containing tailless complex polypeptide 1 (CCT) to regulate β-tubulin folding. J Biol Chem. 289:4490–4502. 2014. View Article : Google Scholar : PubMed/NCBI
40	Essers PB, Klasson TD, Pereboom TC, Mans DA, Nicastro M, Boldt K, Giles RH and MacInnes AW: The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2. Oncogene. 34:771–779. 2015. View Article : Google Scholar : PubMed/NCBI
41	Park SY, Choi HK, Jo SH, Seo J, Han EJ, Choi KC, Jeong JW, Choi Y and Yoon HG: YAF2 promotes TP53-mediated genotoxic stress response via stabilization of PDCD5. Biochim Biophys Acta. 1853:1060–1072. 2015. View Article : Google Scholar : PubMed/NCBI
42	Choi HK, Choi Y, Park ES, Park SY, Lee SH, Seo J, Jeong MH, Jeong JW, Jeong JH, Lee PC, et al: Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response. Nat Commun. 6:73902015. View Article : Google Scholar : PubMed/NCBI
43	Zhuge C, Sun X, Chen Y and Lei J: PDCD5 functions as a regulator of p53 dynamics in the DNA damage response. J Theor Biol. 388:1–10. 2016. View Article : Google Scholar : PubMed/NCBI
44	Murshed F, Farhana L, Dawson MI and Fontana JA: NF-κB p65 recruited SHP regulates PDCD5-mediated apoptosis in cancer cells. Apoptosis. 19:506–517. 2014. View Article : Google Scholar : PubMed/NCBI
45	Park SY, Choi HK, Choi Y, Kwak S, Choi KC and Yoon HG: Deubiquitinase OTUD5 mediates the sequential activation of PDCD5 and p53 in response to genotoxic stress. Cancer Lett. 357:419–427. 2015. View Article : Google Scholar : PubMed/NCBI
46	Cui X, Choi HK, Choi YS, Park SY, Sung GJ, Lee YH, Lee J, Jun WJ, Kim K, Choi KC and Yoon HG: DNAJB1 destabilizes PDCD5 to suppress p53-mediated apoptosis. Cancer Lett. 357:307–315. 2015. View Article : Google Scholar : PubMed/NCBI
47	Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B and Bao JK: Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
48	Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar : PubMed/NCBI
49	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
50	Pucci B, Kasten M and Giordano A: Cell cycle and apoptosis. Neoplasia. 2:291–299. 2000. View Article : Google Scholar : PubMed/NCBI
51	Leng C, Li Y, Qin J, Ma J, Liu X, Cui Y, Sun H, Wang Z, Hua X, Yu Y, et al: Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+T cells. Oncol Rep. 35:699–708. 2016. View Article : Google Scholar : PubMed/NCBI
52	Dong Y, Sun Q and Zhang X: PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 8:2171–2186. 2017.PubMed/NCBI
53	Bardhan K, Anagnostou T and Boussiotis VA: The PD1:PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 7:5502016. View Article : Google Scholar : PubMed/NCBI
54	Zhang J, Wei W, Jin HC, Ying RC, Zhu AK and Zhang FJ: Programmed cell death 2 protein induces gastric cancer cell growth arrest at the early S phase of the cell cycle and apoptosis in a p53-dependent manner. Oncol Rep. 33:103–110. 2015. View Article : Google Scholar : PubMed/NCBI
55	Granier CJ, Wang W, Tsang T, Steward R, Sabaawy HE, Bhaumik M and Rabson AB: Conditional inactivation of PDCD2 induces p53 activation and cell cycle arrest. Biol Open. 3:821–831. 2014. View Article : Google Scholar : PubMed/NCBI
56	Sun Z, Li S, Kaufmann AM and Albers AE: miR-21 increases the programmed cell death 4 gene-regulated cell proliferation in head and neck squamous carcinoma cell lines. Oncol Rep. 32:2283–2289. 2014. View Article : Google Scholar : PubMed/NCBI
57	Xia L, Wen H, Han X, Tang J and Huang Y: Luteinizing hormone inhibits cisplatin-induced apoptosis in human epithelial ovarian cancer cells. Oncol Lett. 11:1943–1947. 2016.PubMed/NCBI
58	Gao F, Ding L, Zhao M, Qu Z, Huang S and Zhang L: The clinical significance of reduced programmed cell death 5 expression in human gastrointestinal stromal tumors. Oncol Rep. 28:2195–2199. 2012. View Article : Google Scholar : PubMed/NCBI
59	McDermott DF and Atkins MB: PD-1 as a potential target in cancer therapy. Cancer Med. 2:662–673. 2013.PubMed/NCBI
60	Mo Z, Liu J, Zhang Q, Chen Z, Mei J, Liu L, Yang S, Li H, Zhou L and You Z: Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncol Lett. 12:944–950. 2016.PubMed/NCBI
61	Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H and Afonja O: Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep. 18:1387–1393. 2007.PubMed/NCBI
62	Fassan M, Cagol M, Pennelli G, Rizzetto C, Giacomelli L, Battaglia G, Zaninotto G, Ancona E, Ruol A and Rugge M: Programmed cell death 4 protein in esophageal cancer. Oncol Rep. 24:135–139. 2010.PubMed/NCBI
63	González-Villasana V, Nieves-Alicea R, McMurtry V, Gutiérrez-Puente Y and Tari AM: Programmed cell death 4 inhibits leptin-induced breast cancer cell invasion. Oncol Rep. 27:861–866. 2012.PubMed/NCBI
64	Barboza N, Minakhina S, Medina DJ, Balsara B, Greenwood S, Huzzy L, Rabson AB, Steward R and Schaar DG: PDCD2 functions in cancer cell proliferation and predicts relapsed leukemia. Cancer Biol Ther. 14:546–555. 2013. View Article : Google Scholar : PubMed/NCBI
65	Zidovetzki R, Johnson DA, Arndt-Jovin DJ and Jovin TM: Rotational mobility of high-affinity epidermal growth factor receptors on the surface of living A431 cells. Biochemistry. 30:6162–6166. 1991. View Article : Google Scholar : PubMed/NCBI
66	Wu SL, Taylor AD, Lu Q, Hanash SM, Im H, Snyder M and Hancock WS: Identification of potential glycan cancer markers with sialic acid attached to sialic acid and up-regulated fucosylated galactose structures in epidermal growth factor receptor secreted from A431 cell line. Mol Cell Proteomics. 12:1239–1249. 2013. View Article : Google Scholar : PubMed/NCBI
67	Zhang F, Wang S, Yin L, Yang Y, Guan Y, Wang W, Xu H and Tao N: Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging. Anal Chem. 87:9960–9965. 2015. View Article : Google Scholar : PubMed/NCBI
68	Stanton P, Richards S, Reeves J, Nikolic M, Edington K, Clark L, Robertson G, Souter D, Mitchell R, Hendler FJ, et al: Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br J Cancer. 70:427–433. 1994. View Article : Google Scholar : PubMed/NCBI
69	Ozaki T and Nakagawara A: Role of p53 in cell death and human cancers. Cancers (Basel). 3:994–1013. 2011. View Article : Google Scholar : PubMed/NCBI
70	Drosten M, Sum EY, Lechuga CG, Simón-Carrasco L, Jacob HK, García-Medina R, Huang S, Beijersbergen RL, Bernards R and Barbacid M: Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. Proc Natl Acad Sci USA. 111:pp. 15155–15160. 2014; View Article : Google Scholar : PubMed/NCBI
71	Zhang HT, Wang YL, Zhang J and Zhang QX: Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53. Tumour Biol. 35:1403–1409. 2014. View Article : Google Scholar : PubMed/NCBI
72	Ranganathan S, Joseph J and Mehta JL: Aspirin inhibits human coronary artery endothelial cell proliferation by upregulation of p53. Biochem Biophys Res Commun. 301:143–146. 2003. View Article : Google Scholar : PubMed/NCBI
73	Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
74	Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M and Green DR: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 303:1010–1014. 2004. View Article : Google Scholar : PubMed/NCBI
75	Nakazawa K, Dashzeveg N and Yoshida K: Tumor suppressor p53 induces miR-1915 processing to inhibit Bcl-2 in the apoptotic response to DNA damage. FEBS J. 281:2937–2944. 2014. View Article : Google Scholar : PubMed/NCBI
76	Wang H, Ye Y, Chui JH, Zhu GY, Li YW, Fong DW and Yu ZL: Oridonin induces G2/M cell cycle arrest and apoptosis through MAPK and p53 signaling pathways in HepG2 cells. Oncol Rep. 24:647–651. 2010.PubMed/NCBI
77	Ou X, Lu Y, Liao L, Li D, Liu L, Liu H and Xu H: Nitidine chloride induces apoptosis in human hepatocellular carcinoma cells through a pathway involving p53, p21, Bax and Bcl-2. Oncol Rep. 33:1264–1274. 2015. View Article : Google Scholar : PubMed/NCBI
78	Zhou Y and Ho WS: Combination of liquiritin, isoliquiritin and isoliquirigenin induce apoptotic cell death through upregulating p53 and p21 in the A549 non-small cell lung cancer cells. Oncol Rep. 31:298–304. 2014. View Article : Google Scholar : PubMed/NCBI